AFP was measured in serum samples using microchip capillary electrophoresis and a liquid-phase binding assay on the uTASWako i30 automated analyzer (Fujifilm Wako Pure Chemical Industries, Osaka, Japan).
Utaswako i30
Manufactured by Fujifilm
Sourced in Japan
The UTASWako i30 is a laboratory equipment used for analytical purposes. It is a compact and automated system designed for efficient and accurate analysis of various samples.
Automatically generated - may contain errors
Lab products found in correlation
4 protocols using utaswako i30
1
Serum AFP Measurement via Microchip CE
2
Automated Biomarker Quantification
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
AFP and PIVKA-II were measured using microchip capillary electrophoresis and a liquid-phase binding assay on the uTASWako i30 automated analyzer (Fujifilm Wako Pure Chemical Industries, Osaka, Japan).
3
Serum AFP Measurement via Microchip CE
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
AFP was measured in serum samples using microchip capillary electrophoresis and a liquid-phase binding assay on the uTASWako i30 automated analyzer (Fujifilm Wako Pure Chemical Industries, Osaka, Japan).
4
Tumor Marker Analysis in Korea
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
This study was conducted at Wonju Severance Christian Hospital, a tertiary university-a liated hospital located in Wonju, Republic of Korea. Two-year data of tumor marker test results between 2017 and 2018 were collected retrospectively from our laboratory information system (LIS). The tumor marker test items included in our study were as follows: alpha-fetoprotein (AFP), beta-human chorionic gonadotropin (HCG), cancer antigen 15 - 3 (CA15-3), cancer antigen 19 - 9 (CA19-9), cancer antigen 72 - 4 (CA72-4), cancer antigen 125 (CA125), carcinoembryonic antigen (CEA), protein induced by vitamin K absence-II (PIVKA), prostatespeci c antigen (PSA), squamous cell carcinoma antigen (SCC), and thyroglobulin antigen (TG).
Tumor markers were measured using the following automated analyzers: the ADVIA Centaur ® XP immunoassay system (Siemens Healthineers, Erlangen, Germany) for CA19-9, CA125, CEA, and PSA; the Cobas ® e 601 module (Roche Diagnostics, Basel, Switzerland) for CA15-3, CA72-4, HCG, SCC, and TG; and the uTASwako i30 (Wako Diagnostics, Osaka, Japan) for AFP and PIVKA. This study was approved by the institutional review board (IRB) of Wonju Severance Christian Hospital (IRB no. CR319041) and the requirement for informed consent was waived.
Tumor markers were measured using the following automated analyzers: the ADVIA Centaur ® XP immunoassay system (Siemens Healthineers, Erlangen, Germany) for CA19-9, CA125, CEA, and PSA; the Cobas ® e 601 module (Roche Diagnostics, Basel, Switzerland) for CA15-3, CA72-4, HCG, SCC, and TG; and the uTASwako i30 (Wako Diagnostics, Osaka, Japan) for AFP and PIVKA. This study was approved by the institutional review board (IRB) of Wonju Severance Christian Hospital (IRB no. CR319041) and the requirement for informed consent was waived.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!